GSK Augmentin ES Conversion Rate Reaches 31%; XR Filing Imminent
GlaxoSmithKline is converting about one-third of Augmentin suspension Rxs to the ES-600 formulation, GSK Chief Operating Officer Bob Ingram told securities analysts Feb. 14
GlaxoSmithKline is converting about one-third of Augmentin suspension Rxs to the ES-600 formulation, GSK Chief Operating Officer Bob Ingram told securities analysts Feb. 14